tapebrief
MTD · Q4 2025

MTD · Q1 2025 Earnings

Cautious

Mettler Toledo

Reported May 7, 2026

30-second summary

Mettler beat its own Q1 EPS guide by $0.16–$0.31 (adjusted EPS $8.91 vs. $8.60–$8.75; +9% YoY) and local-currency sales grew 3%, in line with the ~3% guide — though LC ex-acquisitions was just +1%, signaling thinner underlying momentum than the headline conveys. FY EPS guidance was raised $0.25 at both ends to $46.30–$46.95 (+8% to +10%) while FY LC growth was reaffirmed at ~4%. The Q2 EPS guide of $10.70–$10.85 implies +6% to +8% growth — broadly in line with Q1's +9% rather than a step-up — leaving the FY frame dependent on H2 acceleration that has not yet been quantified.

Headline numbers

EPS

Q1 FY2025

$8.91

Revenue

Q1 FY2025

$0.95B

+7.0% YoY

Gross margin

Q1 FY2025

58.7%

Free cash flow

Q1 FY2025

$0.12B

Operating margin

Q1 FY2025

26.0%

Key financials

Q1 FY2025
MetricQ1 FY2025YoYQ4 FY2025QoQ
Revenue$0.95B+7.0%$1.13B-16.2%
EPS$8.91—$13.36-33.3%
Gross margin58.7%—59.8%-110bps
Operating margin26.0%—32.1%-610bps
Free cash flow$0.12B—$0.19B-36.2%

Guidance

FY2026 EPS guidance raised despite Q1 local currency sales growth disappointing; Q2 EPS outlook accelerates to high-single-digits.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted EPSQ1 FY2025$8.60 to $8.75$8.91+$0.16 to $0.31 above guideBeat
Local Currency Sales GrowthQ1 FY2025approximately 3%1%-2 percentage points below guideMissed

New guidance

MetricPeriodGuideYoY
Adjusted EPSQ2 FY2026$10.70 to $10.85—
Local Currency Sales GrowthQ2 FY2026approximately 3%—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
Adjusted EPS
FY2026
$46.05 to $46.70$46.30 to $46.95+$0.25 to $0.65 (midpoint +$0.45)Raised

Reaffirmed unchanged this quarter: Local Currency Sales Growth (approximately 4%)

Other KPIs

Q1 FY2025
SegmentQ1 FY2025
Adjusted Operating Profit$246.2 million
Adjusted Operating Margin26.0%
Local Currency Sales Growth (ex-acquisitions)1%
Adjusted EPS Growth9%

Management tone

The LC headline met guide, but ex-acquisitions LC growth of +1% is the more important signal. Reported LC sales of +3% matched the ~3% Q1 guide, but the 2pp gap between consolidated LC (+3%) and LC ex-acquisitions (+1%) means M&A is doing material work in the headline. The FY ~4% LC frame was reaffirmed without disaggregating the organic-vs-acquisition contribution — investors should press for that bridge.

The FY EPS raise reads as a cost-execution flow-through, not a demand upgrade. The $0.25 raise at both ends of the FY EPS range matches the Q1 beat magnitude almost exactly — meaning management did not bank any incremental confidence beyond what already showed up in Q1. Combined with the reaffirmed (not raised) FY LC growth frame, the EPS raise is mechanical pass-through rather than improved outlook. Management's framing — "good performance in an increasingly uncertain market environment… solid execution of our margin initiatives" — emphasizes execution, not demand.

The Q2 EPS guide of $10.70–$10.85 (+6% to +8%) is broadly consistent with Q1's +9%. The Q2 range against the FY +8% to +10% target does not require a heroic H2, but it does require sustained mid-to-high single digit EPS growth across the back half. The reaffirmed FY ~4% LC frame combined with a Q2 ~3% LC guide leaves H2 LC growth implicitly in the ~4–5% area — achievable but not yet visible in the print.

Recurring themes management leaned on this quarter:

Tariff cost mitigation and supply chain optimizationNear-term margin pressure with planned full-year recoveryGeographic and end-market diversity as defensive strengthInnovation-driven growth in Lab and Product InspectionUncertainty in China and broader macroeconomic softnessOperational execution and agility through uncertain environment

Risks management surfaced:

Ongoing global trade disputes and tariffs creating customer demand uncertaintyPotential for new or retaliatory tariffs not factored into guidanceGeopolitical tensions and elevated risk to core market outlookSlower market conditions especially in ChinaFood retail market weakness

Q&A highlights

Dan Leonard · UBS

China revenue growth forecast for 2025 broken down between industrial and lab; quantification of on-shoring opportunity for the company

China expected down slightly on reported basis for full year; lab up low single digit, industrial down low single digit. Q2: lab down low single digit, industrial down mid single digit. On-shoring represents future upside but not yet material; company well-positioned with portfolio and Spinnaker program to capture opportunities as factories scale.

China full year: lab up low single digit, industrial down low single digitChina Q2: lab down low single digit, industrial down mid single digitOn-shoring impact: not yet of meaningful size but expected upside in quarters/years to comeCompany positioned through Spinnaker program to identify on-shoring opportunities

Patrick Donnelly · Citi

Tariff impact breakdown by source geography and mitigation approach (supply chain, cost savings, pricing); industrial market customer sentiment and forecast changes

Direct China imports now ~$50M (down from <$100M); total US imports ~$250M with significant Switzerland exposure. Mexico manufacturing expanded; pricing expected to increase from 2% to 3% including surcharges. Industrial softness driven by customer delays on larger projects and China caution; automation demand trends remain strong long-term despite near-term uncertainty.

China imports: $50M (previously <$100M)Total US imports: ~$250MMexico imports now higher than ChinaPricing increase: 2% to 3% for full year

Jack Meehan · Nefron Research

Evidence of tariff-related pull-forward in customer orders; process analytics business strength in bioprocessing sector

No meaningful pull-forward of orders observed in Q1 or April trends despite tariff concerns; customers not making short-term planning changes. Process analytics showing healthy recovery driven by biopharma manufacturing increases; single-use and multi-use sensors both growing; prior year stocking issues now fully resolved.

No significant tariff-driven order pull-forward observedProcess analytics growing driven by increased biopharma manufacturingSingle-use sensors showing healthy recovery after prior year issuesMulti-use sensors also growing

Dan Arias · Stifel

Mexico manufacturing expansion scope beyond original pipette tips and life sciences reagents; tariff mitigation pricing stickiness if de-escalation occurs; competitive position in China long-term

Mexico facility significantly expanded beyond original scope; now includes products across lab, industrial, and food retail segments. Surcharges provide flexibility to adjust if tariff rates change; pricing may have stickiness but supply chain investments are permanent. Mexico still below China in magnitude but growing; China competitive position strong due to local manufacturing, supply chain, R&D, and market understanding.

Mexico facility expanded to include lab, industrial, food retail productsMexico manufacturing expansion permanent and ongoing for ~2 yearsChinese exposure minimal for US products; most products manufactured in ChinaChina tariff exposure on imports small; long-term competitive position strong

Brandon Coolard · Stifel

Geographic specificity of delayed orders/project push-outs; China customer characteristics and tariff exposure; free cash flow guidance maintenance despite headwinds

Order delays isolated to China with wait-and-see behavior from customers uncertain about tariffs; Western markets remain optimistic with strong customer activity. China business primarily serves local market (15% to multinationals); exposure to exporters minimal. Free cash flow guidance maintained; company managed strong Q1 FCF up 17% per share excluding bonus timing.

Order delays primarily China-specificChina business: 15% or less to multinationals; mostly private companiesMinimal exposure to exporters in ChinaQ1 free cash flow up 17% per share (excluding bonus timing)

Answers to last quarter's watch list

Whether Q1 FY2026 adjusted EPS lands in the $8.60–$8.75 guide and LC sales hit ~3%. Both met or exceeded: EPS beat at $8.91 (+$0.16–$0.31 above) and reported LC sales were +3%, in line with the guide. The FY +8% to +10% EPS frame survives and was raised by $0.25. Caveat: LC ex-acquisitions was only +1%, so organic momentum is softer than the headline.
Resolved positively
Whether the tariff narrative reverts to a quantified offset bridge. The press release does not provide a quantified bridge. The static "current levels" posture appears to hold.
Continue monitoring
Europe product inspection durability. Europe LC was disclosed at just +1% in Q1 — the +12% reported USD figure is almost entirely FX. Product-line detail at the regional level was not disclosed in the press release.
Continue monitoring
Q1 product-line breakdown — particularly Lab and core industrial. Not disclosed in the press release. Without segment detail, the composition of the +3% LC / +1% ex-acquisitions print is not verifiable from the release alone.
Not resolved
Any quantification of the pharma/life sciences pipeline. No quantification disclosed in the press release.
Continue monitoring
China LC growth vs. management's "comfortable at mid-single digit" framing. China-specific LC growth not disclosed in the press release. Asia/RoW LC at +5% is the only regional read available.
Continue monitoring

What to watch into next quarter

Whether Q2 FY2026 LC sales clear the ~3% guide, and whether the ex-acquisitions gap narrows. A second consecutive print with a wide organic-vs-reported gap would put the FY ~4% LC frame under pressure even if the headline holds.

Whether FY LC growth is held, narrowed, or cut on the Q2 print. Reaffirming ~4% after another quarter of soft organic growth would signal H2 visibility is genuine; a cut would confirm the Q1 reaffirmation was positional.

Q2 adjusted operating margin trajectory. Q1 at 26.0% (-80bps YoY) is the seasonal low. Investors should look for Q2 sequential expansion; flat-to-down would signal tariff and FX drag are not abating as projected.

Restoration of a quantified tariff offset bridge. Two quarters into the "current levels assumed" posture, the absence of a quantified bridge means any policy escalation would land without a defensive narrative in place.

Segment commentary on product inspection in Europe. With Europe LC at just +1%, durability of the product-inspection bull case management has anchored on needs fresh confirmation on the call.

Sources

  1. Mettler-Toledo Q1 2026 press release (SEC 8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1037646/000103764626000019/ex-991mtd8xkq12026.htm
  2. Prior Tapebrief briefs: MTD Q4-2025, Q3-2025, Q2-2025.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.